HealthEquity (NASDAQ:HQY) Given New $122.00 Price Target at Citizens Jmp

HealthEquity (NASDAQ:HQY) had its price objective boosted by equities research analysts at Citizens Jmp from $117.00 to $122.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. Citizens Jmp’s price objective suggests a potential upside of 23.68% from the company’s previous close.

A number of other equities analysts have also recently issued reports on HQY. Royal Bank Of Canada increased their target price on HealthEquity from $109.00 to $110.00 and gave the stock an “outperform” rating in a report on Wednesday, September 3rd. KeyCorp dropped their price objective on shares of HealthEquity from $125.00 to $120.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 8th. Weiss Ratings reiterated a “hold (c+)” rating on shares of HealthEquity in a report on Wednesday, October 8th. Barrington Research restated an “outperform” rating and issued a $125.00 target price on shares of HealthEquity in a report on Friday, August 29th. Finally, BMO Capital Markets assumed coverage on shares of HealthEquity in a research report on Thursday, November 13th. They issued a “market perform” rating and a $100.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $119.86.

HealthEquity Stock Performance

Shares of HQY opened at $98.64 on Thursday. HealthEquity has a one year low of $74.07 and a one year high of $116.65. The company has a market cap of $8.50 billion, a PE ratio of 59.78, a P/E/G ratio of 1.47 and a beta of 0.18. The stock has a 50-day moving average of $96.42 and a 200-day moving average of $96.88. The company has a debt-to-equity ratio of 0.47, a current ratio of 4.23 and a quick ratio of 4.23.

HealthEquity (NASDAQ:HQY) last announced its quarterly earnings results on Wednesday, December 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.11. HealthEquity had a return on equity of 12.04% and a net margin of 11.49%.The business had revenue of $322.16 million for the quarter, compared to analyst estimates of $320.92 million. During the same quarter in the prior year, the company earned $0.78 earnings per share. The company’s quarterly revenue was up 7.2% on a year-over-year basis. HealthEquity has set its FY 2026 guidance at 3.870-3.950 EPS. On average, equities research analysts predict that HealthEquity will post 2.32 EPS for the current fiscal year.

Insider Activity

In other HealthEquity news, EVP Delano Ladd sold 1,500 shares of the stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $104.56, for a total value of $156,840.00. Following the completion of the sale, the executive vice president owned 75,479 shares in the company, valued at approximately $7,892,084.24. This trade represents a 1.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Michael Henry Fiore sold 1,781 shares of HealthEquity stock in a transaction that occurred on Tuesday, October 7th. The stock was sold at an average price of $88.21, for a total transaction of $157,102.01. Following the transaction, the executive vice president directly owned 49,795 shares in the company, valued at approximately $4,392,416.95. This represents a 3.45% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 10,781 shares of company stock valued at $1,016,707. 1.50% of the stock is currently owned by corporate insiders.

Institutional Trading of HealthEquity

A number of institutional investors and hedge funds have recently modified their holdings of HQY. Vanguard Group Inc. lifted its holdings in HealthEquity by 2.9% during the third quarter. Vanguard Group Inc. now owns 8,746,255 shares of the company’s stock worth $828,883,000 after acquiring an additional 243,549 shares during the period. Wasatch Advisors LP increased its position in shares of HealthEquity by 3.4% during the 3rd quarter. Wasatch Advisors LP now owns 6,307,675 shares of the company’s stock valued at $597,778,000 after purchasing an additional 206,611 shares during the last quarter. Invesco Ltd. raised its stake in shares of HealthEquity by 50.6% during the 1st quarter. Invesco Ltd. now owns 2,446,198 shares of the company’s stock worth $216,171,000 after purchasing an additional 821,425 shares during the period. AQR Capital Management LLC raised its stake in shares of HealthEquity by 59.3% during the 3rd quarter. AQR Capital Management LLC now owns 1,764,268 shares of the company’s stock worth $167,200,000 after purchasing an additional 656,820 shares during the period. Finally, Westfield Capital Management Co. LP boosted its holdings in shares of HealthEquity by 35.7% in the 3rd quarter. Westfield Capital Management Co. LP now owns 1,716,658 shares of the company’s stock worth $162,688,000 after buying an additional 451,450 shares during the last quarter. 99.55% of the stock is owned by hedge funds and other institutional investors.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.